Evidence map›Paper›PMID 29319935›Full record

Trial reportClinical pharmacology in drug development2018

Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics.

Naidong Ye, Scott A Monk, Pankaj Daga, David M Bender, Laura B Rosen, Jamie Mullen, Margaret C Minkwitz, Alan R Kugler

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology in drug development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02039180 (A Phase 1, Open-label, Randomized, Single-dose, 3-period Cross-over, Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02039180 phase1completednot on this map

A Phase 1, Open-label, Randomized, Single-dose, 3-period Cross-over, Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects

TypeinterventionalSponsorAstraZenecaRan2014 to 2014Enrolled1ConditionsHealthy Volunteers, Pharmacologic ActionArmsAZD3293 oral solution, AZD3293 tablet formulation A, AZD3293 tablet formulation B
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Naidong YeAstraZeneca, Cambridge, MA, USA.
Scott A MonkLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
Pankaj DagaAstraZeneca, Cambridge, MA, USA.
David M BenderLilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
Laura B RosenAstraZeneca, Cambridge, MA, USA.
Jamie MullenAstraZeneca, Cambridge, MA, USA.
Margaret C MinkwitzAstraZeneca, Cambridge, MA, USA.
Alan R KuglerAstraZeneca, Cambridge, MA, USA.
AstraZeneca (South Korea) · KRAstraZeneca (United States) · USEli Lilly (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relative bioavailability of lanabecestat administered as 2 tablet formulations versus an oral solution was investigated. This phase 1 single-center, open-label, randomized, 3-period crossover study involved healthy male and nonfertile female subjects aged 18-55 years (NCT02039180). Subjects received a single 50-mg lanabecestat dose as solution, tablet A, or tablet B on day 1 of each crossover period; 14 of 16 subjects completed the study. Relative bioavailability based on plasma lanabecestat AUC

Indexed as

Administration, OralAdultAmyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesBiological AvailabilityCross-Over StudiesDrug CompoundingFemaleGastric MucosaHumansHydrogen-Ion ConcentrationImidazolesMaleMiddle AgedPharmaceutical SolutionsSpiro CompoundsAmyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesBACE1 protein, humanImidazoleslanabecestatPharmaceutical SolutionsSpiro CompoundsTabletsAlzheimer'sAZD3293BACE1bioavailabilitypharmacokinetics

Identifiers

PMID29319935
PMCPMC5947295
OpenAlexW2783004697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.